Copyright Reports & Markets. All rights reserved.

Global Sirolimus API Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Purity
    • 1.3.1 Overview: Global Sirolimus API Consumption Value by Purity: 2021 Versus 2025 Versus 2032
    • 1.3.2 98%-99%
    • 1.3.3 Above 99%
  • 1.4 Market Analysis by Product Grade
    • 1.4.1 Overview: Global Sirolimus API Consumption Value by Product Grade: 2021 Versus 2025 Versus 2032
    • 1.4.2 Pharmaceutical Grade
    • 1.4.3 Cosmetic Grade
  • 1.5 Market Analysis by Customer Type
    • 1.5.1 Overview: Global Sirolimus API Consumption Value by Customer Type: 2021 Versus 2025 Versus 2032
    • 1.5.2 Pharmaceutical Companies
    • 1.5.3 Medical Device Manufacturers
    • 1.5.4 CDMO/Research Institutions
  • 1.6 Market Analysis by Application
    • 1.6.1 Overview: Global Sirolimus API Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Tablets
    • 1.6.3 Oral Solution
    • 1.6.4 Gel
    • 1.6.5 Others
  • 1.7 Global Sirolimus API Market Size & Forecast
    • 1.7.1 Global Sirolimus API Consumption Value (2021 & 2025 & 2032)
    • 1.7.2 Global Sirolimus API Sales Quantity (2021-2032)
    • 1.7.3 Global Sirolimus API Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Concord Biotech
    • 2.1.1 Concord Biotech Details
    • 2.1.2 Concord Biotech Major Business
    • 2.1.3 Concord Biotech Sirolimus API Product and Services
    • 2.1.4 Concord Biotech Sirolimus API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Concord Biotech Recent Developments/Updates
  • 2.2 Curia Italy
    • 2.2.1 Curia Italy Details
    • 2.2.2 Curia Italy Major Business
    • 2.2.3 Curia Italy Sirolimus API Product and Services
    • 2.2.4 Curia Italy Sirolimus API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Curia Italy Recent Developments/Updates
  • 2.3 Lonza Biologics Tuas Pte Ltd
    • 2.3.1 Lonza Biologics Tuas Pte Ltd Details
    • 2.3.2 Lonza Biologics Tuas Pte Ltd Major Business
    • 2.3.3 Lonza Biologics Tuas Pte Ltd Sirolimus API Product and Services
    • 2.3.4 Lonza Biologics Tuas Pte Ltd Sirolimus API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Lonza Biologics Tuas Pte Ltd Recent Developments/Updates
  • 2.4 Apotex Pharmachem
    • 2.4.1 Apotex Pharmachem Details
    • 2.4.2 Apotex Pharmachem Major Business
    • 2.4.3 Apotex Pharmachem Sirolimus API Product and Services
    • 2.4.4 Apotex Pharmachem Sirolimus API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Apotex Pharmachem Recent Developments/Updates
  • 2.5 Chunghwa Chemical Synthesis & Biotech
    • 2.5.1 Chunghwa Chemical Synthesis & Biotech Details
    • 2.5.2 Chunghwa Chemical Synthesis & Biotech Major Business
    • 2.5.3 Chunghwa Chemical Synthesis & Biotech Sirolimus API Product and Services
    • 2.5.4 Chunghwa Chemical Synthesis & Biotech Sirolimus API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Chunghwa Chemical Synthesis & Biotech Recent Developments/Updates
  • 2.6 Hisun Pharmaceutical
    • 2.6.1 Hisun Pharmaceutical Details
    • 2.6.2 Hisun Pharmaceutical Major Business
    • 2.6.3 Hisun Pharmaceutical Sirolimus API Product and Services
    • 2.6.4 Hisun Pharmaceutical Sirolimus API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Hisun Pharmaceutical Recent Developments/Updates
  • 2.7 Fujian Kerui Pharmaceutical
    • 2.7.1 Fujian Kerui Pharmaceutical Details
    • 2.7.2 Fujian Kerui Pharmaceutical Major Business
    • 2.7.3 Fujian Kerui Pharmaceutical Sirolimus API Product and Services
    • 2.7.4 Fujian Kerui Pharmaceutical Sirolimus API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Fujian Kerui Pharmaceutical Recent Developments/Updates
  • 2.8 Lunan New Time Bio Tech
    • 2.8.1 Lunan New Time Bio Tech Details
    • 2.8.2 Lunan New Time Bio Tech Major Business
    • 2.8.3 Lunan New Time Bio Tech Sirolimus API Product and Services
    • 2.8.4 Lunan New Time Bio Tech Sirolimus API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Lunan New Time Bio Tech Recent Developments/Updates
  • 2.9 BrightGene Bio-Medical Technology
    • 2.9.1 BrightGene Bio-Medical Technology Details
    • 2.9.2 BrightGene Bio-Medical Technology Major Business
    • 2.9.3 BrightGene Bio-Medical Technology Sirolimus API Product and Services
    • 2.9.4 BrightGene Bio-Medical Technology Sirolimus API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 BrightGene Bio-Medical Technology Recent Developments/Updates
  • 2.10 Hangzhou Zhongmei Huadong Pharmaceutical
    • 2.10.1 Hangzhou Zhongmei Huadong Pharmaceutical Details
    • 2.10.2 Hangzhou Zhongmei Huadong Pharmaceutical Major Business
    • 2.10.3 Hangzhou Zhongmei Huadong Pharmaceutical Sirolimus API Product and Services
    • 2.10.4 Hangzhou Zhongmei Huadong Pharmaceutical Sirolimus API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Hangzhou Zhongmei Huadong Pharmaceutical Recent Developments/Updates
  • 2.11 Chongqing Daxin Pharmaceutical
    • 2.11.1 Chongqing Daxin Pharmaceutical Details
    • 2.11.2 Chongqing Daxin Pharmaceutical Major Business
    • 2.11.3 Chongqing Daxin Pharmaceutical Sirolimus API Product and Services
    • 2.11.4 Chongqing Daxin Pharmaceutical Sirolimus API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Chongqing Daxin Pharmaceutical Recent Developments/Updates
  • 2.12 North China Pharmaceutical Huasheng
    • 2.12.1 North China Pharmaceutical Huasheng Details
    • 2.12.2 North China Pharmaceutical Huasheng Major Business
    • 2.12.3 North China Pharmaceutical Huasheng Sirolimus API Product and Services
    • 2.12.4 North China Pharmaceutical Huasheng Sirolimus API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 North China Pharmaceutical Huasheng Recent Developments/Updates
  • 2.13 Zhejiang Wild Wind Pharmaceutical
    • 2.13.1 Zhejiang Wild Wind Pharmaceutical Details
    • 2.13.2 Zhejiang Wild Wind Pharmaceutical Major Business
    • 2.13.3 Zhejiang Wild Wind Pharmaceutical Sirolimus API Product and Services
    • 2.13.4 Zhejiang Wild Wind Pharmaceutical Sirolimus API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Zhejiang Wild Wind Pharmaceutical Recent Developments/Updates
  • 2.14 Yangzhou Lianao Biopharmaceutical
    • 2.14.1 Yangzhou Lianao Biopharmaceutical Details
    • 2.14.2 Yangzhou Lianao Biopharmaceutical Major Business
    • 2.14.3 Yangzhou Lianao Biopharmaceutical Sirolimus API Product and Services
    • 2.14.4 Yangzhou Lianao Biopharmaceutical Sirolimus API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Yangzhou Lianao Biopharmaceutical Recent Developments/Updates

3 Competitive Environment: Sirolimus API by Manufacturer

  • 3.1 Global Sirolimus API Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Sirolimus API Revenue by Manufacturer (2021-2026)
  • 3.3 Global Sirolimus API Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Sirolimus API by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Sirolimus API Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Sirolimus API Manufacturer Market Share in 2025
  • 3.5 Sirolimus API Market: Overall Company Footprint Analysis
    • 3.5.1 Sirolimus API Market: Region Footprint
    • 3.5.2 Sirolimus API Market: Company Product Type Footprint
    • 3.5.3 Sirolimus API Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Sirolimus API Market Size by Region
    • 4.1.1 Global Sirolimus API Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Sirolimus API Consumption Value by Region (2021-2032)
    • 4.1.3 Global Sirolimus API Average Price by Region (2021-2032)
  • 4.2 North America Sirolimus API Consumption Value (2021-2032)
  • 4.3 Europe Sirolimus API Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Sirolimus API Consumption Value (2021-2032)
  • 4.5 South America Sirolimus API Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Sirolimus API Consumption Value (2021-2032)

5 Market Segment by Purity

  • 5.1 Global Sirolimus API Sales Quantity by Purity (2021-2032)
  • 5.2 Global Sirolimus API Consumption Value by Purity (2021-2032)
  • 5.3 Global Sirolimus API Average Price by Purity (2021-2032)

6 Market Segment by Application

  • 6.1 Global Sirolimus API Sales Quantity by Application (2021-2032)
  • 6.2 Global Sirolimus API Consumption Value by Application (2021-2032)
  • 6.3 Global Sirolimus API Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Sirolimus API Sales Quantity by Purity (2021-2032)
  • 7.2 North America Sirolimus API Sales Quantity by Application (2021-2032)
  • 7.3 North America Sirolimus API Market Size by Country
    • 7.3.1 North America Sirolimus API Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Sirolimus API Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Sirolimus API Sales Quantity by Purity (2021-2032)
  • 8.2 Europe Sirolimus API Sales Quantity by Application (2021-2032)
  • 8.3 Europe Sirolimus API Market Size by Country
    • 8.3.1 Europe Sirolimus API Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Sirolimus API Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Sirolimus API Sales Quantity by Purity (2021-2032)
  • 9.2 Asia-Pacific Sirolimus API Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Sirolimus API Market Size by Region
    • 9.3.1 Asia-Pacific Sirolimus API Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Sirolimus API Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Sirolimus API Sales Quantity by Purity (2021-2032)
  • 10.2 South America Sirolimus API Sales Quantity by Application (2021-2032)
  • 10.3 South America Sirolimus API Market Size by Country
    • 10.3.1 South America Sirolimus API Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Sirolimus API Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Sirolimus API Sales Quantity by Purity (2021-2032)
  • 11.2 Middle East & Africa Sirolimus API Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Sirolimus API Market Size by Country
    • 11.3.1 Middle East & Africa Sirolimus API Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Sirolimus API Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Sirolimus API Market Drivers
  • 12.2 Sirolimus API Market Restraints
  • 12.3 Sirolimus API Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Sirolimus API and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Sirolimus API
  • 13.3 Sirolimus API Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Sirolimus API Typical Distributors
  • 14.3 Sirolimus API Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Sirolimus API market size was valued at US$ 243 million in 2025 and is forecast to a readjusted size of US$ 379 million by 2032 with a CAGR of 6.2% during review period.
    Sirolimus API is a macrolide fermentation-based active pharmaceutical ingredient, industrially obtained primarily through fermentation with Streptomyces hygroscopicus, followed by extraction, separation, purification, crystallization, and refining to form an API that meets pharmaceutical quality standards. Sirolimus exerts immunosuppressive and antiproliferative effects by binding to FKBP12 and inhibiting the mTOR pathway. Its traditional core application is in the preparation of anti-rejection drugs for kidney transplantation, but its applications have expanded to areas such as lymphangioleiomyomatosis (LAM), tuberous sclerosis-related facial angiofibroma, treatment of certain tumors, and sirolimus-eluting coronary stents.
    The future market will continue to be driven by stable demand for immunosuppressive therapy in organ transplantation, but growth will mature. Sirolimus is already a relatively mature mTOR inhibitor and faces competition from other immunosuppressive therapies such as Tacrolimus, Cyclosporine, Mycophenolate, and Everolimus. Therefore, the traditional transplant market is unlikely to experience explosive growth. However, the increase in global transplant surgeries, long-term immunosuppressive therapy, and the penetration of generic drugs in emerging markets will maintain stable API demand.
    The demand structure for sirolimus is expanding from traditional oral immunosuppressants to "multiple dosage forms + multiple indications." In addition to traditional tablets and oral solutions, the FDA has approved sirolimus topical gel for tuberous sclerosis-related facial angiofibroma; nab-sirolimus has entered the field of oncology treatment such as PEComa. For API suppliers, the significance of this change is not simply increasing the kilograms, but rather the differentiated requirements for purity, particle size, impurities, stability, and customer quality agreements imposed by different dosage forms, further enhancing the added value of high-specification API products. Drug elution devices are a very distinctive application of Sirolimus API, and their growth rate may be higher than that of traditional transplant drugs. Sirolimus has a strong anti-proliferative effect and can be used as an active ingredient in the coating of coronary drug-eluting stents to reduce the risk of restenosis.
    Report Scope
    This report is a detailed and comprehensive analysis for global Sirolimus API market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Purity and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Sirolimus API market size and forecasts, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/kg), 2021-2032
    Global Sirolimus API market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/kg), 2021-2032
    Global Sirolimus API market size and forecasts, by Purity and by Application, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/kg), 2021-2032
    Global Sirolimus API market shares of main players, shipments in revenue ($ Million), sales quantity (Tons), and ASP (US$/kg), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Sirolimus API
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Sirolimus API market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Concord Biotech, Curia Italy, Lonza Biologics Tuas Pte Ltd, Apotex Pharmachem, Chunghwa Chemical Synthesis & Biotech, Hisun Pharmaceutical, Fujian Kerui Pharmaceutical, Lunan New Time Bio Tech, BrightGene Bio-Medical Technology, Hangzhou Zhongmei Huadong Pharmaceutical, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Sirolimus API market is split by Purity and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Purity, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market Segmentation
    Market segment by Purity
    98%-99%
    Above 99%
    Market segment by Product Grade
    Pharmaceutical Grade
    Cosmetic Grade
    Market segment by Customer Type
    Pharmaceutical Companies
    Medical Device Manufacturers
    CDMO/Research Institutions
    Market segment by Application
    Tablets
    Oral Solution
    Gel
    Others
    Major players covered
    Concord Biotech
    Curia Italy
    Lonza Biologics Tuas Pte Ltd
    Apotex Pharmachem
    Chunghwa Chemical Synthesis & Biotech
    Hisun Pharmaceutical
    Fujian Kerui Pharmaceutical
    Lunan New Time Bio Tech
    BrightGene Bio-Medical Technology
    Hangzhou Zhongmei Huadong Pharmaceutical
    Chongqing Daxin Pharmaceutical
    North China Pharmaceutical Huasheng
    Zhejiang Wild Wind Pharmaceutical
    Yangzhou Lianao Biopharmaceutical
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    Chapter Outline
    Chapter 1, to describe Sirolimus API product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Sirolimus API, with price, sales quantity, revenue, and global market share of Sirolimus API from 2021 to 2026.
    Chapter 3, the Sirolimus API competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Sirolimus API breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Purity and by Application, with sales market share and growth rate by Purity, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Sirolimus API market forecast, by regions, by Purity, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Sirolimus API.
    Chapter 14 and 15, to describe Sirolimus API sales channel, distributors, customers, research findings and conclusion.

    Buy now